[Optimizing antidepressant pharmacotherapy in a case of inflammatory bowel disease and major depression].
OBJECTIVE
In the framework of a case report on a patient suffering from major depression and inflammatory bowel disease we address the pharmacotherapeutical options in case of subtherapeutic mirtazapine levels.


METHODS
We applied therapeutic drug monitoring (TDM) and cytochrome P450 2D6 genotyping, and switched to an orodispersible tablet.


CONCLUSIONS
Thus, mirtazapine plasma levels could be raised and clinical improvement of the depressive symptoms was achieved.
Klinik und Poliklinik für Psychiatrie und Psychotherapie, Universitätsklinikum Leipzig. Frank.Schmidt2@medizin.uni-leipzig.de
Frank Martin
FM
Schmidt
Carsten
C
Tennert
Daniel
D
Teupser
Hubertus
H
Himmerich
D000483:Alleles; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003093:Colitis, Ulcerative / Q000097:blood / Q000175:diagnosis* / Q000523:psychology; D003131:Combined Modality Therapy; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D003865:Major Depressive Disorder / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000523:psychology; D004305:Dose-Response Relationship, Drug; D006580:Genetic Carrier Screening; D006801:Humans; D008099:Liver / Q000201:enzymology; D008297:Male; D019804:Mesalamine / Q000009:adverse effects / Q000627:therapeutic use; D008657:Metabolic Clearance Rate / Q000235:genetics; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D010343:Patient Admission
D000893:Anti-Inflammatory Agents; D000929:Antidepressive Agents, Tricyclic; D008803:Mianserin; D019804:Mesalamine; D000078785:Mirtazapine; D019389:Cytochrome P-450 CYP2D6